The largest community of pharma leaders

Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

REDWOOD CITY, Calif.–(BUSINESS WIRE)– #RSV–The first adult participants have been dosed in a Phase 2 study of MV-012-968, Meissa’s intranasal live attenuated vaccine candidate against RSV.

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles